Publications by authors named "A Mejean"
Article Synopsis
- The review focuses on the recent advancements in treatment options for metastatic renal cell carcinoma (mRCC), highlighting the importance of selecting appropriate first- and second-line therapies based on the latest evidence.
- First-line treatments include immune checkpoint inhibitor combinations and tyrosine kinase inhibitors, with four regimens approved internationally; however, treatment decisions are complicated by the absence of head-to-head trials and standardized biomarkers.
- Clinicians must consider various factors, such as the IMDC risk score and patient preferences, when transitioning between treatment lines to ensure personalized and effective care for mRCC patients.
The synoptic operative report (SOR) is a model with several advantages but still not enough adopted. We studied the performance of a SOR template (FileMaker Pro®, FMP) versus the usual narrative operative report (NOR) template on DxCare® software (DXC) of the urology department at the Georges-Pompidou European Hospital by comparing the number of completed data, the completeness rate, the writing time, and the writing speed and by analyzing the learning curve. Over an 11-week period between March and June 2021, 118 case-control OR for 59 laparoscopic or open, partial or total nephrectomy procedures, for all indications were prospectively created.
View Article and Find Full Text PDFArticle Synopsis
- In 2022, nivolumab was approved for high-risk patients with localized invasive muscle urothelial carcinoma after surgery, prompting a study to explore its real-world use.
- Conducted at two hospitals from July 2022 to January 2024, the study included 200 patients; 70 were deemed high-risk, but nearly half did not receive treatment due to various reasons.
- The outcomes showed a median disease-free survival of 11.34 months for treated patients, and while nivolumab was well-tolerated, 25% discontinued it due to side effects, with findings supporting prior research on its effectiveness.
Introduction: Microphthalmia Transfactor Family (MiTF) translocation renal cell carcinomas (RCCs) represent a rare subtype of renal cell cancers. They are diagnosed in young patients and have a poor prognosis. The aim of our study was to analyze the clinical and pathological features of patients with MiTF RCC.
View Article and Find Full Text PDFPurpose: This study aimed to evaluate the ability of Kidney Stone Calculator (KSC), a flexible ureteroscopy surgical planning software, to predict the lithotripsy duration with both holmium:YAG (Ho:YAG) and thulium fiber laser (TFL).
Methods: A multicenter prospective study was conducted from January 2020 to April 2023. Patients with kidney or ureteral stones confirmed at non-contrast computed tomography and treated by flexible ureteroscopy with laser lithotripsy were enrolled.